Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03851445 · ClinicalTrials.gov registry record · Phase 2
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
A Phase 2 study of Previously Treated Non-Small Cell Lung Cancer, sponsored by SWOG Cancer Research Network.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10,000
- Enrollment target
- 20
- Study locations
NCT03851445: Recruiting Phase 2 study of Previously Treated Non-Small Cell Lung Cancer, sponsored by SWOG Cancer Research Network.
NCT03851445 is a Phase 2 study of Previously Treated Non-Small Cell Lung Cancer that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 10,000 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (7419% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03851445, a Phase 2 study of Previously Treated Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by SWOG Cancer Research Network.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Primary Outcome
The tissue submission will be measured by the proportion of patients who register to this screening study for whom a tissue sample is submitted.
Conditions Studied
Interventions
- DRUG Screening Platform
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Alabama
- Veterans Administration Medical Center - Birmingham - Birmingham
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis - Daphne
- Thomas Hospital - Fairhope
- Mobile Infirmary Medical Center - Mobile
- University of South Alabama Mitchell Cancer Institute - Mobile
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland - Saraland
Arizona
- CTCA at Western Regional Medical Center - Goodyear
- Kingman Regional Medical Center - Kingman
- Cancer Center at Saint Joseph's - Phoenix
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2019-02-06 |
| Est. Completion | 2029-01-28 |
| Phase | Phase 2 |
What NCT03851445 shows while recruiting
NCT03851445 is an interventional study that assigns participants to a tested intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (7419% higher).
The record links to 1 condition, with Previously Treated Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Screening Platform is the first listed.
NCT03851445 names 20 study sites across 3 states, led by Alaska, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT03851445 about?
NCT03851445 is a clinical study titled "Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer". This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will deter...
What is the current status of trial NCT03851445?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10,000 participants. The study started on 2019-02-06. Estimated completion is 2029-01-28.
What conditions does trial NCT03851445 study?
This clinical trial studies the following conditions: Previously Treated Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03851445?
The interventions under investigation include: Screening Platform (DRUG).
Who is sponsoring clinical trial NCT03851445?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03851445 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03851445's enrollment target sits among peer trials
10,000 1st of 2000 higher than 2,000 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI